{
  "ticker": "TRVI",
  "company_name": "Trevi Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05962151",
      "title": "Refractory Chronic Cough Improvement Via NAL ER (RIVER)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Refractory Chronic Cough",
      "start_date": "2023-11-30",
      "completion_date": "2025-01-06",
      "enrollment": 0,
      "sponsor": "Trevi Therapeutics"
    },
    {
      "nct_id": "NCT05964335",
      "title": "Cough Reduction in IPF With Nalbuphine ER",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Idiopathic Pulmonary Fibrosis",
      "start_date": "2024-02-06",
      "completion_date": "2025-04-24",
      "enrollment": 0,
      "sponsor": "Trevi Therapeutics"
    },
    {
      "nct_id": "NCT07015398",
      "title": "A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Participants",
      "start_date": "2025-06-30",
      "completion_date": "2025-09-26",
      "enrollment": 0,
      "sponsor": "Trevi Therapeutics"
    },
    {
      "nct_id": "NCT02143973",
      "title": "Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus",
      "status": "COMPLETED",
      "phase": "PHASE2, PHASE3",
      "condition": "Uremic Pruritus, Pruritus",
      "start_date": "2014-09",
      "completion_date": "2016-01",
      "enrollment": 0,
      "sponsor": "Trevi Therapeutics"
    },
    {
      "nct_id": "NCT02373215",
      "title": "Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Uremic Pruritus",
      "start_date": "2013-04",
      "completion_date": "2013-11",
      "enrollment": 0,
      "sponsor": "Trevi Therapeutics"
    },
    {
      "nct_id": "NCT03497975",
      "title": "PRISM Study-Pruritus Relief Through Itch Scratch Modulation",
      "status": "COMPLETED",
      "phase": "PHASE2, PHASE3",
      "condition": "Prurigo Nodularis",
      "start_date": "2018-08-07",
      "completion_date": "2023-02-24",
      "enrollment": 0,
      "sponsor": "Trevi Therapeutics"
    },
    {
      "nct_id": "NCT02174432",
      "title": "Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis",
      "status": "COMPLETED",
      "phase": "PHASE2, PHASE3",
      "condition": "Prurigo Nodularis, Nodularis Prurigo, Prurigo",
      "start_date": "2015-08-15",
      "completion_date": "2017-09-03",
      "enrollment": 0,
      "sponsor": "Trevi Therapeutics"
    },
    {
      "nct_id": "NCT02143648",
      "title": "Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus",
      "status": "COMPLETED",
      "phase": "PHASE2, PHASE3",
      "condition": "Uremic Pruritus, Pruritus",
      "start_date": "2014-06",
      "completion_date": "2015-07",
      "enrollment": 0,
      "sponsor": "Trevi Therapeutics"
    },
    {
      "nct_id": "NCT02174419",
      "title": "Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis",
      "status": "COMPLETED",
      "phase": "PHASE2, PHASE3",
      "condition": "Prurigo Nodularis, Nodularis Prurigo, Prurigo, Pruritus",
      "start_date": "2015-03",
      "completion_date": "2016-08",
      "enrollment": 0,
      "sponsor": "Trevi Therapeutics"
    },
    {
      "nct_id": "NCT07036029",
      "title": "NAL ER IPF Respiratory Function and Safety Study",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Idiopathic Pulmonary Fibrosis",
      "start_date": "2025-08-21",
      "completion_date": "2026-02",
      "enrollment": 0,
      "sponsor": "Trevi Therapeutics"
    }
  ],
  "summary": {
    "total_trials": 13,
    "by_phase": {
      "PHASE2": 3,
      "PHASE1": 5,
      "PHASE2, PHASE3": 5
    },
    "by_status": {
      "COMPLETED": 11,
      "RECRUITING": 1,
      "UNKNOWN": 1
    },
    "active_trials": 1,
    "completed_trials": 11,
    "conditions": [
      "Healthy Participants",
      "Idiopathic Pulmonary Fibrosis",
      "Nalbuphine, Hepatic Impairment",
      "Nalbuphine, Opioid Abuse",
      "Prurigo Nodularis",
      "Prurigo Nodularis, Nodularis Prurigo, Prurigo",
      "Prurigo Nodularis, Nodularis Prurigo, Prurigo, Pruritus",
      "Refractory Chronic Cough",
      "Uremic Pruritus",
      "Uremic Pruritus, Pruritus"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:22:30.237766",
    "search_query": "Trevi Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Trevi+Therapeutics,+Inc."
  }
}